全球前列腺癌:流行病学更新、差异与筛查意义
本综述综合系统综述、荟萃分析、随机筛查试验及人群登记数据,更新全球前列腺癌发病率、死亡率、患病率、危险因素、差异与筛查意义。当前趋势需结合筛查政策、诊断强度、MRI与生物标志物可及性、遗传易感性及卫生系统能力解读。组织化风险适配路径整合PSA、MRI、生物标志物与基线风险,或可在保留早期检测获益的同时减少过度诊断与不公平。
要点
- 年龄、家族史、 ancestry及胚系风险是前列腺癌最强决定因素。
- 多数可改变暴露因素作用较弱且不一致,宜置于心血管代谢健康与生存照护框架。
- 组织化风险适配路径整合PSA、MRI、生物标志物与基线风险可平衡获益与过度诊断。
核心结论
- 前列腺癌进展取决于预防转移性疾病、最小化过度治疗及公平实施现代诊断。
- 当前趋势需结合筛查政策、诊断强度、MRI与生物标志物可及性、遗传易感性及卫生系统能力解读。
研究设计与样本
- 综述综合近期系统综述、荟萃分析、随机筛查试验及人群登记数据,辅以里程碑历史研究。
主要发现
- 年龄、家族史、ancestry及胚系风险仍是前列腺癌最强决定因素。
- 多数可改变暴露因素作用较弱且不一致,更适合置于心血管代谢健康与生存照护框架内。
- 组织化风险适配路径整合PSA、MRI、生物标志物与基线风险,或可更好保留早期检测获益并减少过度诊断与不公平。
临床怎么用
- 临床应关注年龄、家族史、ancestry及胚系风险等最强决定因素。
- 可改变暴露因素的管理宜纳入心血管代谢健康与生存照护。
- 探索组织化风险适配路径整合PSA、MRI、生物标志物与基线风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer epidemiology is evolving because of three simultaneous factors: a rising global burden, population aging, and renewed debate about how early detection can reduce advanced disease without returning to non-risk-adapted PSA testing. This Review provides an updated overview of prostate cancer incidence, mortality, prevalence, risk factors, disparities, and screening implications. METHODS: We synthesized recent systematic reviews, meta-analyses, randomized screening trials, and population-based registry data, supplemented by landmark historical studies. RESULTS: Current trends cannot be interpreted without accounting for screening policy, diagnostic intensity, access to MRI and biomarkers, inherited susceptibility, and health-system capacity. Age, family history, ancestry, and germline risk remain the strongest determinants. Most modifiable exposures are weaker and inconsistent, and are better framed within cardiometabolic health and survivorship care. Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity. CONCLUSIONS: Progress will depend on preventing metastatic disease, minimizing overtreatment, and implementing modern diagnostics equitably.
引用
- Bernardino RM, Nguyen DD, Carlsson SV, et al. Prostate cancer worldwide: updated epidemiology, disparities, and screening implications. Prostate Cancer Prostatic Dis. 2026. PMID: 42946767. doi:10.1038/s41391-026-01167-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。